Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost in idiopathic pulmonary fibrosis with pulmonary hypertension
NCT00109681Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2005
- Primary completion
- Oct 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iloprost in pulmonary hypertension (PH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Safety. Started Apr 2005; status: completed.
02
Drugs
iloprost
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00109681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109681.